Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Commercial Officer, Aesthetics and Therapeutics Aubrey Rankin - President, Innovation and Technology Conference Call Participants Seamus Fernandez - Guggenheim Terence Flynn - Goldman Sachs Annabel Samimy - Stifel David Ams ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2021 Results Conference Call May 10, 2021 4:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Commercial Officer, Aesthetics and Therapeutics Aubrey Rankin - President, Innovation and Technology Conference Call Participants Ken Cacciatore - Cowen & Company Seamus Fernandez - Guggenheim Terence Flynn - Goldman Sachs Ann ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2020 Earnings Conference Call February 22, 2021 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations and ESG Mark Foley - President and Chief Executive Officer Toby Schilke - Chief Financial Officer Roman Rubio - Senior Vice President Clinical Development Dustin Sjuts - Chief Commercial Officer, Therapeutics & Aesthetics Abhay Joshi - Chief Operating Officer and President of R&D and Product Operation Conference Call Participants Ken Cacciator ...

| --- | --- | --- | |---------------------------------------------------------|-------|-------| | | | | | | | | | Daring To Make A Difference Daring To Make A Difference | | | | COMPANY PRESENTATION NOVEMBER 2020 | | | Forward-Looking Statements Safe Harbor / Market Data 2 This presentation contains forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics and outlook; the market ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Jeanie Herbert - Head of Investor Relations Mark Foley - President & Chief Executive Officer Toby Schilke - Chief Financial Officer Dustin Sjuts - Chief Commercial Officer, Therapeutics & Aesthetics Conference Call Participants Ken Cacciatore - Cowen & Company Annabel Samimy - Stifel Terence Flynn - Goldman Sachs David Amsellem - Piper Sandler Kush Patel - Guggenheim Tim Lugo - William ...

Daring To Make A Difference COMPANY PRESENTATION September 2020 Prevance FORWARD-LOOKING STATEMENTS / SAFE HARBOR / MARKET DATA This presentation contains forward-looking statements, including forward-statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics and outlook; the growth of markets for global neuromodulators, dermal fillers and aesthetics fintech platforms; the process and timing of, and ability to complete, current and an ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Jeanie Herbert - Head, Investor Relations & Corporate Communications Mark Foley - President & Chief Executive Officer Dustin Sjuts - Chief Commercial Officer, Aesthetics & Therapeutics Toby Schilke - Chief Financial Officer Abhay Joshi - Chief Operating Officer & President of R&D & Product Operations Conference Call Participants Terence Flynn - Goldman Sachs Stacy Ku - Cowen & Company Dav ...

| --- | --- | --- | |--------------------------------|-------|-------| | | | | | | | | | | | | | Daring To Make A Difference | | | | COMPANY PRESENTATION JUNE 2020 | | | This presentation contains forward-looking statements, including forward-statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics and outlook; the process and timing of, and ability to complete, current and anticipated future clinical development of our investigatio ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Mark Foley - President and Chief Executive Officer Toby Schilke - Chief Financial Officer Dr. Abhay Joshi - Chief Operating Officer and President of R&D and Product Operations Dustin Sjuts - Chief Commercial Officer of Aesthetics and Therapeutics Conference Call Participants Jacob Hughes - Wells Fargo Securit ...

1 Daring to Make a Difference Company Presentation March 2020 『·revance Forward-Looking Statements / Safe Harbor / Market Data 2 This presentation contains forward-looking statements, including forward-statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics and outlook; the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational product candidates, including anticip ...